Sprint Precision Technologies
688605
Jiangsu Jingxue Insulation Technology
301010
Global Infotech
300465
Hydsoft Technology
301316
SGSG Science&Technology
300561
CN Stock MarketDetailed Quotes
600645 Vcanbio Cell & Gene Engineering Corp.,Ltd.
- 20.49
- +0.25+1.24%
Market Closed Dec 12 15:00 CST
9.59BMarket Cap89.09P/E (TTM)
20.52High20.19Low52.67KlotVolume20.26Open20.24Pre Close107.38MTurnover1.13%Turnover Ratio90.26P/E (Static)467.95MShares24.0852wk High2.65P/B9.58BFloat Cap12.8852wk Low22.26Limit Up467.77MShs Float79.58Historical High18.22Limit Down1.63%Amplitude1.23Historical Low--Dividend TTM20.39Avg Price24.33KlotAsk--Div YieldTTM100Lot Size26.43KlotBid
Vcanbio Cell & Gene Engineering Corp.,Ltd. News
Vcanbio Cell & Gene Engineering (SHSE:600645) Seems To Use Debt Quite Sensibly
Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. Report for the third quarter of 2024
vcanbio cell & gene engineering corp.,ltd. (600645.SH) released its performance for the first three quarters, with a net income of 0.134 billion yuan, a year-on-year increase of 0.76%.
vcanbio cell & gene engineering corp.,ltd. (600645.SH) disclosed its third quarter report for 2024, achieving operating income in the first three quarters...
vcanbio cell & gene engineering corp.,ltd. (600645.SH): VUM02 injection receives drug clinical trial approval notice.
GeLongHui, September 9th | vcanbio cell & gene engineering corp.,ltd. (600645.SH) announced that its wholly-owned subsidiary wuhan guanggu vcan pharmaceutical co.,ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the approval of VUM02 injection for the treatment of systemic sclerosis on September 9. VUM02 injection (human umbilical cord mesenchymal stem cell injection) is a freeze-preserved stem cell preparation independently developed by the company, which is a new drug of human umbilical cord mesenchymal stem cells (UC-MSC) prepared from screened healthy newborn umbilical cord tissue through in vitro separation, amplification, harvesting, and cryopreservation, with clinical intentions.
Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Don't Show The Whole Picture
Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd.
vcanbio cell & gene engineering corp.,ltd. (600645.SH) released its semi-annual performance, with a net income of 85.19 million yuan, a year-on-year increase of 3.04%.
vcanbio cell & gene engineering corp.,ltd. (600645.SH) disclosed its 2024 interim report, during the reporting period, the company achieved a revenue of 8.02...
Further Weakness as Vcanbio Cell & Gene Engineering (SHSE:600645) Drops 7.1% This Week, Taking Three-year Losses to 22%
Vcanbio Cell & Gene Engineering Corp., Ltd. (600645.SH): The company has completed the repurchase of 2.58% of its shares at a total cost of 0.2 billion yuan.
On August 1st, Gelunhui reported that Vcanbio Cell & Gene Engineering (600645.SH) announced that on July 31, 2024, the company completed a buyback and had actually repurchased 12,052,740 shares of the company, accounting for 2.58% of the total share capital, with a maximum repurchase price of 21.15 yuan/share, a minimum repurchase price of 15.11 yuan/share, an average repurchase price of 16.59 yuan/share, and a total fund amount of 0.2 billion yuan.
Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Share Price Could Signal Some Risk
vcanbio cell & gene engineering corp.,ltd. (600645.SH) has cumulatively repurchased 2.14% of its shares, costing 168 million yuan.
VCANBIO Cell & Gene Engineering Corp., Ltd. (600645.SH) announced that as of June 30, 2024, the company has repurchased a cumulative total of 10,028,800 shares, accounting for 2.14% of the company's total share capital. The highest purchase price was 21.15 yuan/share and the lowest purchase price was 15.11 yuan/share. The total amount paid was 168 million yuan (excluding transaction fees).
vcanbio cell & gene engineering corp.,ltd. (600645.SH): Cumulative expenditure of 161 million yuan repurchased 2.06% of the shares.
As of June 26, 2024, vcanbio Cell & Gene Engineering Corp., Ltd. (600645.SH) announced that it has repurchased a cumulative total of 9,618,840 shares of the company through centralized bidding trading, accounting for 2.06% of the total share capital of the company. Compared with the last disclosure, it has increased by 0.14%. The highest purchase price was 21.15 yuan/share and the lowest was 15.11 yuan/share. The total amount paid was 161,070,220.30 yuan (excluding transaction commission and other fees).
Is Vcanbio Cell & Gene Engineering (SHSE:600645) Using Too Much Debt?
vcanbio cell & gene engineering corp.,ltd. (600645.SH): Received notice of acceptance for clinical trial application of pharmaceutical VUM02 injection.
On June 20th, Gelunhui reported that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., has recently obtained the "Notice of Acceptance" for the clinical trial application of the new indication for VUM02 injection (human umbilical cord-derived mesenchymal stem cell injection) issued by the Drug Evaluation Center (CDE) of the National Medical Products Administration. VUM02 injection, a frozen stem cell preparation independently developed by our company, is a new drug of umbilical cord-derived mesenchymal stem cells (UC-MSC) prepared by screening healthy newborn umbilical cord tissue, separating, amplifying, harvesting, and freezing. Clinical
Zhongyuan Xiehe (600645.SH) has repurchased a total of 8.983 million shares at a cost of 151 million yuan
Zhongyuan Xiehe (600645.SH) issued an announcement. As of May 31, 2024, the company has made a total number of repurchases...
Do Its Financials Have Any Role To Play In Driving Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Stock Up Recently?
Zhongyuan Kyowa (600645.SH): Storage business includes neonatal cord blood hematopoietic stem cells, etc.
Gelonghui, May 14, 丨 Zhongyuan Xiehe (600645.SH) said on the investor interactive platform that the company's storage business includes neonatal umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental subpluripotent stem cells, and adult immune cells, adipose mesenchymal stem cells, and dental pulp mesenchymal stem cells. In terms of cell therapy research and development, the company's current VUM02 injection derived from umbilical cord mesenchymal stem cells has been approved for IND. Ind. indications include decompensated liver cirrhosis, idiopathic pulmonary fibrosis, slow-acute (subacute) liver failure, acute respiratory distress syndrome, and grade II to IV acute when hormone therapy fails
Zhongyuan Kyowa (600645.SH): The concept of synthetic biology is quite broad. Currently, the company focuses on the development of stem cell drugs
Gelonghui, May 8, 丨 Zhongyuan Xiehe (600645.SH) said on the investor interactive platform that the company's main business includes preparation and storage of cell tests in the field of “precision prevention”; research, production and marketing of in vitro diagnostic raw materials, in vitro diagnostic reagents and devices in the field of “accurate diagnosis”; research and development of clinical applications of stem cells and immune cells in the “cell therapy” field; forming a “precision medicine” industry chain. The concept of synthetic biology is quite broad. Currently, the company focuses on the research and development of stem cell drugs.
Zhongyuan Xiehe (600645.SH): A total of 1.65% of the company's shares have been repurchased
Gelonghui, May 6, 丨 Zhongyuan Xiehe (600645.SH) announced that as of April 30, 2024, the company had repurchased a total of 7,707,940 shares, accounting for 1.65% of the company's total share capital. The highest purchase price was 17.95 yuan/share, the lowest price was 15.11 yuan/share, and the total amount paid was 125,389,095.38 yuan (not including transaction fees).
